We conducted a multicenter retrospective analysis to evaluate the efficacy of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. We enrolled 36 patients with pathologically proven, unresectable combined hepatocellular and cholangiocarcinoma treated with systemic chemotherapy. The log-rank test determined the significance of each prognostic factor. Elevated alphafetoprotein, carcinoembryonic antigen and carbohydrate antigen 19-9 levels were observed in 58.3%, 16.7% and 38.9% of patients, respectively. First-line chemotherapy included platinum-containing regimens consisting of gemcitabine/cisplatin (n = 12) and fluorouracil/cisplatin (n = 11), sorafenib (n = 5) and others (n = 8). The median overall and progression-free survival times were 8.9 and 2.8 months,
Hakko Kirin, NanoCarrier, Ono Pharmaceutical and Takeda Pharmaceutical. J.F. is a consultant/advisor to and has received honoraria and research funding from Astellas Pharma, Bayer AG, Chugai Pharmaceutical, Eisai, Eli Lilly Japan K. K respectively, with an overall response rate of 5.6%. Prognostic factors associated with negative outcomes included poor performance status, no prior primary tumor resection, a Child-Pugh class of B, and elevated carcinoembryonic antigen levels with a hazard ratio of 2.25, 2.48, 3.25 and 2.84 by univariate analysis, respectively.
The median overall survival times of the gemcitabine/cisplatin, fluorouracil/cisplatin, sorafenib and other groups were 11.9, 10.2, 3.5 and 8.1 months, respectively. Multivariate analysis revealed that the overall survival of patients within the sorafenib monotherapy group was poor compared with platinum-containing regimens (HR:
15.83 [95% CI: 2.25-111.43], P = .006). All 7 patients in the sorafenib group had progressive disease, including 2 patients with second-line therapy. In conclusion, the platinum-containing regimens such as gemcitabine/cisplatin were associated with more favorable outcomes than sorafenib monotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
K E Y W O R D S
Cisplatin, drug therapy, gemcitabine, prognosis, sorafenib 
| INTRODUCTION

| MATERIALS AND METHODS
| Patients
Patients with pathologically proven, unresectable or recurrent, CHC treated with systemic chemotherapy from January 2002 to December 2015 were enrolled from 15 institutions in Japan. The exclusion criteria included those with "double cancer," which is defined as CHC by Allen's classification but neither by Goodman's classification nor the WHO classification. In addition, it is practical to treat the more malignant tumor rather than the more indolent one in the case of patients with 2 different types of tumors. Those with "type 3 fibrolamellar tumor," which is defined as CHC by Goodman's classification, but not by Allen's classification, were also excluded. Tumors with high attenuation in >50.0% of the entire tumor in early-phase dynamic CT were defined as "hypervascular type" and those with high attenuation in <50.0% of the entire tumor were defined as "hypovascular type" 
| Systemic chemotherapy regimens
Systemic chemotherapy regimens were determined at the physicians' discretion, including second-line or higher-line treatments after failure with first-line chemotherapy. All patients continued chemotherapy until clinical or radiological disease progression, intolerable adverse events or patient refusal. 12 The overall response rate (ORR) was defined as the proportion of patients who achieved a complete or partial response divided by the total number of patients enrolled in the study. The disease control rate was defined as the proportion of patients who achieved a complete or partial response, or stable disease, divided by the total number of patients enrolled in the study.
| Clinical outcomes
| Statistical analyses
Univariate analysis and multivariate analysis using a Cox regression hazard model were conducted to evaluate prognostic factors for OS. Multivariate analysis was performed by backward selection using factors that had a P-value <.10 in the univariate analysis, because there were too few patients to detect statistical differences by using P-value <.05.
Patient characteristics, the ORR and the disease control rates were compared for each regimen using Fisher's exact test. All statistical analyses were conducted using the Statistical Package for the Social Sciences for Windows, software version 22.0 (IBM, Armonk, NY, USA).
| RESULTS
| Patients
In total, 36 patients were enrolled in this study. The patient characteristics are summarized in Table 1 . A pathological diagnosis was 
| Systemic chemotherapy
Patients treated with first-line systemic chemotherapy were classified into 4 groups according to the treatment regimen ( Table 2) : (1) gemcitabine plus cisplatin (n = 12); (2) Gemcitabine plus cisplatin regimens were administered more frequently in female patients (P = .045) and sorafenib monotherapy exhibited a trend towards being more frequently administered in patients with elevated serum AFP levels (P = .073).
| Clinical outcomes
For the entire cohort, the median OS and PFS times were 8. According to the treatment groups, the median OS times of the fluorouracil plus cisplatin, gemcitabine plus cisplatin, sorafenib monotherapy, and other groups were 11.9 (95% CI: 4.9-18. Figure 3B ). There were no statistical differences in PFS times between the groups. However, none of the patients in the sorafenib monotherapy group achieved disease control, even when patients who received second-line systemic chemotherapy with sorafenib monotherapy were included.
We also compared the efficacies of each treatment type in patients with hypervascular tumors, high levels of AFP and low levels of CEA to confirm the superiority of platinum-containing regimens over sorafenib, even in hepatocellular carcinoma-like tumors (Table 4 ). The median OS times of the sorafenib monotherapy group were shorter than those in the group with a platinum-containing regimen, even in patients with "hypervascular type" tumors (1.6 vs 11.9 months; P = .008). There were similar trends of high AFP levels and low CEA levels for hypervascular tumors, although these trends were not statistically significant. There was no influence of historical trend on the OS times in patients before and after the approval of sorafenib for hepatocellular carcinoma or Fluorouracil plus cisplatin and mitoxantrone 3 (8) Fluorouracil plus cisplatin and epirubicin 2 (6) Fluorouracil plus cisplatin 2 (6) 3. Sorafenib monotherapy, n (%) 5 (14) 4. Others group, n (%)
S-1 monotherapy 4 (11)
Gemcitabine monotherapy 2 (6) Fluorouracil plus interferon 1 (3)
Gemcitabine plus S-1 1 (3) S-1, tegafur/gimeracil/oteracil. 
| DISCUSSION
Combined hepatocellular and cholangiocarcinoma is a rare type of primary liver cancer, which is more common in men and individuals with chronic liver disease caused by hepatitis B or hepatitis C viral infections, and these etiologies are more commonly associated with hepatocellular carcinoma rather than cholangiocarcinoma. 6, 7, [13] [14] [15] With respect to histopathological findings, 2 classical classification systems (Goodman's and Allen's) have been used. Radiological findings of dynamic CT or MRI were reported to be useful in diagnosing whether the tumor is "cholangiocarcinoma-dominant". 16, 17, 19 According to these findings, 69.0% of patients in the present study may have cholangiocarcinoma-dominant tumors. Gemcitabine plus cisplatin showed antitumor activity in biliary tract cancer, 21 and it seems reasonable that gemcitabine plus cisplatin exhibited a better outcome in our study. Another finding that supports the benefit of gemcitabine plus cisplatin is the identification of prognostic factors. Univariate analysis revealed elevated serum CEA levels (not AFP levels) to be a significant poor prognostic factor. This may suggest that we should treat the cholangiocarcinoma component, even in patients with "hepatocellular carcinoma-dominant type" tumors. In addition, it was notable that sorafenib monotherapy did not exhibit better trends compared to platinum-containing regimens, even in patients with "hypervascular type" tumors or elevated serum AFP levels, suggesting that platinum-containing regimens may be more promising than sorafenib, even in unresectable patients with "hepatocellular carcinoma-dominant type" CHC.
There are some reports of systemic chemotherapy for CHC, although these are reports of single cases or case series without detailed descriptions of the chemotherapy regimens (Table 5 ).
22-29
T A B L E 4 Comparison of the overall survival time between the platinum-containing regimens and sorafenib group for hepatocellular carcinoma-like tumors and EGFR were more frequently expressed in CHC than in hepatocellular carcinoma or cholangiocarcinoma, and other reports 31, 32 documented that TP53, AR1D1A/2, PBRM1 and PTEN were expressed in CHC. We hope that more basic research of genetic mutations and subsequent basket trials will advance the treatment of unresectable CHC.
Our study has several limitations. First, is its retrospective design, which could lead to potential selection bias, and second is the small sample size, which could result in type I and type II statis- Despite these limitations, we concluded that, to the best of our knowledge, this is the first report to investigate the efficacy and prognostic factors of several chemotherapy regimens for unresectable CHC. Patients with poor liver function, no prior history of primary tumor resection and elevated serum CEA levels had a poor prognosis. These factors should be used to stratify patients in future clinical trials. In addition, platinum-containing regimens, such as gemcitabine plus cisplatin, which is a current standard of care for unresectable cholangiocarcinoma, represent the most promising among several systemic chemotherapy regimens that are currently being adopted to treat unresectable CHC in a clinical setting. Further investigation is warranted to establish a standard therapy for unresectable CHC.
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